Paweł Zagrodzki
Published: 2002-03-15
GICID: 01.3001.0000.3490
Available language versions: en
Issue: Postepy Hig Med Dosw 2002; 56 (2)
Abstract
Thioredoxin reductase (TrxR) is the first selenoenzyme containing selenocysteine in the active center and FAD as a second prosthetic group. TrxR catalyses the NADPH-dependent reduction of thioredoxin and of many other physiologically important substrates. TrxR exhibits a many-fold increase in the activity in tumor cells and stimulates their proliferation as well the phenotype changes. Some gold compounds and a number of other clinically and experimentally tested drugs have been shown to inhibit TrxR. The involvement of TrxR/Trx/NADPH system in a broad spectrum of cellular processes renders it a potential target for therapeutic approaches.